A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Breast cancer risk can be assessed by examining the epithelial cells found in breast milk, according to preliminary study results presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Nicotine at doses similar to those found in most nicotine replacements therapies did not increase lung cancer tumor incidence, frequency or size, according to results of a mouse study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Results of the NIH-AARP Diet and Health Study revealed that diabetes is associated with lower risk of prostate cancer in men but with higher risk of other cancers in both men and women. The data, to be presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, also showed an association between diabetes and higher cancer mortality rates.
Smoking increases the risk of breast cancer, but the risk differs by obesity status in postmenopausal women, according to data from an analysis of the Women’s Health Initiative observational study.
Scientists have confirmed that metabolic syndrome, a constellation of conditions that increases the risk of heart disease and diabetes, may also increase the risk of the two most common types of liver cancer, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
The U.S. Congress will soon be facing another budget showdown as their sixth continuing resolution expires on April 8, 2011. While the entire government has been without permanent appropriations for nearly six months, the House Republicans and Senate Democrats continue to remain far apart on resolving the fiscal year (FY) 2011 budget.
Cancer Discovery, the newest journal in the robust publication program of the American Association for Cancer Research, will debut at the AACR 102nd Annual Meeting 2011, held here from April 2-6.
Scientists have uncovered a genetic characteristic of metastatic prostate cancer that defines a rare sub-type of this disease. These findings are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, which will debut at the AACR 102nd Annual Meeting 2011, held April 2-6.
Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.
Scientists have identified digoxin as a possible therapy for prostate cancer, using a combination of laboratory science and epidemiology that is unprecedented in its cooperative nature.
A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.
Evidence continues to build that telomeres, cell endings that fray as we age, are affected by stress and are predictive of cancer risk. Scientists will present new groundbreaking research in this area of study at an AACR 102nd Annual Meeting 2011 press conference held on Sunday, April 2 at 2:00 p.m. ET in room W313 of the Orange County Convention Center.
Using new genetic information, scientists have linked a commonly found human genetic variant with both longer telomeres and reduced risk of bladder cancer, according to findings presented at the AACR 102nd Annual Meeting 2011, held April 2-6, and simultaneously published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Results of a study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, lend credence to the idea that improving quality of life affects stress-related biological markers and possibly the health of people with cancer.
The American Association for Cancer Research Annual Meeting continues to be a showcase for the most cutting edge science in cancer, and this year’s meeting, held here April 2-6, will include an increased focus on clinical trials that will impact patient care.
A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
Scientists are continuing their work on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial — known more commonly as the BATTLE trial — and presented updated results at the AACR 102nd Annual Meeting 2011, held here April 2-6.
The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Scientists have identified a biomarker for measuring the success of lung cancer chemoprevention, an emerging frontier in the fight against this disease that has long been stymied by a lack of measureable outcomes. These study results were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
In one of the largest cancer genomics investigations reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients’ healthy cells. This comparison allowed researchers to find mutations that only occurred in the cancer cells.
1) Test conducted in the non-cancerous part of the prostate; 2) May aid in localization of cancer lesion within the prostate gland.
The American Association for Cancer Research will present the Honorable John Edward Porter (R-Ill.) with the 2011 AACR Award for Distinguished Service and Global Impact in Cancer and Biomedical Research. Porter, chairman of Research!America and acting chair of the Foundation for the National Institutes of Health (NIH), was chosen for this special award because of his significant and sustained contributions to cancer and biomedical research, including his leadership of the effort to double the budget of the NIH.
Scientific breakthroughs in personalized medicine, diagnosis and prevention of cancer will take center stage when more than 18,000 people from around the world gather at the Orange County Convention Center in Orlando, Fla., from April 2-6 for the AACR 102nd Annual Meeting 2011.
The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus (HPV) for more than 20 years.
Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel (Taxol), which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas. Her work has also contributed to the understanding of how microtubules function in normal and malignant cells and why stabilization of microtubules is a promising target for drug discovery.
Pier Paolo Pandolfi, M.D., Ph.D., is the recipient of the 2011 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the field of cancer genetics and mouse models for cancer. This work has contributed to new therapies for treating cancers.
Yosef Shiloh, Ph.D., a David and Inez Myers professor in cancer research in the department of Human Molecular Genetics and Biochemistry in the Sackler School of Medicine at Tel Aviv University, Israel, will receive the 51st Annual AACR G.H.A. Clowes Memorial Award for his studies of the cellular DNA damage response and the rare genomic instability syndrome ataxia-telangiectasia (A-T).
The American Association for Cancer Research will recognize leading cancer researchers whose work has significantly contributed to progress in the fight against cancer at the AACR 102nd Annual Meeting 2011. Each recipient will present an educational lecture at the meeting, which will be held April 2-6 at the Orange County Convention Center.
The Pancreatic Cancer Action Network and the American Association for Cancer Research awarded 10 grants to outstanding scientists throughout the country, supporting their innovative research in the field of pancreatic cancer. This year’s total funding level of nearly $3 million represents the largest annual disbursement since the Pancreatic Cancer Action Network introduced the program in 2003. The recipients will be honored at a recognition event scheduled during the AACR 102nd Annual Meeting 2011, held April 2-6, at the Orange County Convention Center in Orlando, Fla.
The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network–AACR Pathway to Leadership Grants. These grants, each totaling $600,000 over five years, will be formally awarded at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.
The American Association for Cancer Research and the Kirk A. and Dorothy P. Landon Foundation will present three INNOVATOR Awards at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research is awarding 50 Minority Scholar in Cancer Research Awards at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research will recognize leaders in the minority cancer community with the Minority-Serving Institution Faculty Scholars in Cancer Research Awards. The 36 recipients will be honored at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research will recognize 27 recipients of the AACR-Thomas J. Bardos Science Education Award for Undergraduate Students at the AACR 102nd Annual Meeting 2011, held here from April 2 to 6.
The AACR would like to congratulate its newest grant recipients at the AACR 102nd Annual Meeting 2011, held April 2-6.
The members of the American Association for Cancer Research have elected Frank McCormick, Ph.D., D.Sc. (hon.), as their president-elect. McCormick is the director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He holds the E. Dixon Heise distinguished professorship in oncology and the David A. Wood distinguished professorship of tumor biology and cancer research at UCSF. Additionally, he is the associate dean of the UCSF School of Medicine and a distinguished professor in residence in the department of microbiology and immunology as well as in the department of biochemistry and biophysics.
Arthur D. Levinson, Ph.D., chairman and former CEO of Genentech Inc., will receive the Fifth Annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR 102nd Annual Meeting 2011, held April 2-6.
The members of the American Association for Cancer Research have elected Frank McCormick, Ph.D., D.Sc. (hon.), as their president-elect. McCormick is the director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He holds the E. Dixon Heise distinguished professorship in oncology and the David A. Wood distinguished professorship of tumor biology and cancer research at UCSF. Additionally, he is the associate dean of the UCSF School of Medicine and a distinguished professor in residence in the department of microbiology and immunology as well as in the department of biochemistry and biophysics.
Since the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, the U.S. Food and Drug Administration (FDA) has met the ambitious implementation deadlines set forth in the law, the agency said Wednesday at a congressional briefing hosted by the American Association for Cancer Research.
In 2009, a historic new law granted the U.S. Food and Drug Administration (FDA) authority to regulate the manufacturing, marketing and sale of tobacco products. The FDA will give an update on the implementation of the Family Smoking Prevention and Tobacco Control Act at a congressional briefing hosted by the American Association for Cancer Research on Wednesday, March 16.
The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network – AACR Pathway to Leadership Grants. These grants, each totaling $600,000 over five years, will be formally awarded at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research will hold its 102nd Annual Meeting at the Orange County Convention Center from April 2-6, 2011.
1) Obese women had a 35 percent increased risk of breast cancer; 2) Risk was similar to increase in estrogen receptor-positive cancer; 3) Obesity may increase risk through mechanisms other than estrogen.
Susan Band Horwitz, Ph.D., will receive the Eighth AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel (Taxol), which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas. Her work has also contributed to the understanding of how microtubules function in normal and malignant cells and why stabilization of microtubules is a promising target for drug discovery.
The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus (HPV) for more than 20 years.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right